Cubicin Becomes Blockbuster, As Cubist Passes on Adynxx Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
The antibiotic developer said it will look to grow its portfolio of marketed products from three to four in 2014. Long-term it’s looking to do more acquisitions, perhaps with tax strategy in mind, but backed away from an option to acquire pain company Adynxx.